Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada. (2024). SKIN The Journal of Cutaneous Medicine, 8(1), s317. https://doi.org/10.25251/skin.8.supp.317